Sankyo and Daiichi are two leading Japanese pharmaceutical companies that have merged to build a new Top 20 Global Pharma Innovator called DAIICHI SANKYO. With a new name, new products and a new office in the UK, this dynamic company is now ready for even more rapid growth in the Cardiovascular and Diabetes markets!
New company name
Sankyo Pharma UK Ltd has become one of the rising stars in the industry over the last three years by building a new organisation, introducing new processes, investing in new technology and developing our people to successfully launch the antihypertensive Olmetec® into one of the most competitive markets in the UK. The company is now ready to enter the next phase of its development by merging with another Japanese company called Daiichi and changing its name to DAIICHI SANKYO UK LTD.
Sankyo was the third biggest pharmaceutical company in Japan, and its merger with Daiichi, the sixth largest pharma company in Japan, is going to create a new Global Pharma Innovator with 18,400 employees and worldwide sales of £4.6 billion! This means that DAIICHI SANKYO will become the second largest pharmaceutical company in Japan and the 19th largest in the world!
Excellent product pipeline
The merger of DAIICHI SANKYO has also created an outstanding new product pipeline, and the company will be investing 22% of its global net sales into research and development. In fact, DAIICHI SANKYO has more than 50 new chemical entities in its pipeline, and ten of the most promising new
compounds are in the Company’s core cardiovascular and diabetes therapy areas:
| CS-747 Anti-platelet |
DU-176b Anti-coagulant |
 |
| CS-8663 Hypertension |
DZ-697b Anti-platelet |
|
| CS-011 Diabetes |
CS-3030 Anti-coagulant |
|
| CS-917 Diabetes |
CS-8080 Arteriosclerosis |
|
| CS-9883 Ischaemia |
P2Y-12 Anti-platelet |
|
Investment in the UK DAIICHI SANKYO moved to a brand new office in Gerrards Cross, Buckinghamshire during June 2006 to provide the much-needed space and facilities to continue building the UK business in the future.
In addition, DAIICHI SANKYO will be locating their European Research & Development Division in the same office building in the UK later this year. This demonstrates the importance of the UK in the company’s global clinical development programme, and it will provide an ideal opportunity to build even stronger Key Opinion Leader relationships in this country.
New DAIICHI SANKYO offices in Gerrards Cross Ambitious vision DAIICHI SANKYO UK is an ambitious organisation, and is aiming to become ‘Our Target Prescribers’ 1st Choice for Cardiovascular Medicine’ by developing, recognising and rewarding high performance. The company also has a clear set of values, and these have formed the foundation of a unique set of competencies that define the way we work:
- Obsessed about achievement
- Before our customers ask for it
- Integrity in our actions
- Dare to be different
- United. We go for it!
The performance-driven culture of DAIICHI SANKYO UK involves setting high standards, working hard, playing hard and treating people as individuals, together with a high level of accountability and the transparency of individual performance measures across the whole company. This is reinforced with Quarterly Performance Reviews to ensure that the highest performers in every part of the company receive the competitive salaries, bonuses and promotions they deserve, regardless of how long they have been in their roles.
Skills and career development are also driven proactively at DAIICHI SANKYO UK, and Performance Development Plans are reviewed and updated on a quarterly basis to ensure that they remain relevant. These plans may involve individual coaching or attending a training course, though they may also involve taking on additional team responsibilities, contributing to a multi-functional project team, or being seconded into another role in the company on a short-term basis.
Great place to work
With strong leadership, innovative plans, great people and competitive rewards, DAIICHI SANKYO UK is a brilliant place to work for high performers with the drive and capability to succeed. The company was also nominated as the 15th most desirable employer to work for in the 2005–6 Pf Survey. And don’t just take our word for it: 85% of our staff completed our anonymous Internal Staff Survey in May 2006, and rated the company as follows:
96% Daiichi Sankyo UK is a good company to work for
91% I am proud to work for Daiichi Sankyo UK
90% I am clear about what I am expected to achieve
89% I am encouraged to make my own decisions
88% I believe that our future business prospects are bright
86% I can rely on my manager to give me the support I need
84% I received sufficient training to do my job
84% High performers are recognised and rewarded
83% Communication in my part of the business is good
83% Daiichi Sankyo UK offers a good range of benefits to me
DAIICHI SANKYO UK High Performers in April 2006
10 things you may not know about DAIICHI SANKYO
1st company to develop a statin for hyperlipidaemia
1st company to develop a glitazone for diabetes
Establish how practices will spend their indicative budgets. Which services will they support?
Identify how your products can deliver value to these plans. How can you help deliver cost savings and improve health outcomes?
2nd largest pharmaceutical company in Japan
3rd best cash launch of an AIIA antihypertensive in the UK
4% AIIA unit market share with Olmetec in less than 21/2 years
4.6 billion pounds of worldwide net sales
15th most desirable employer to work for in 2005–6 Pf Survey
19th largest pharmaceutical company in the world
22% global net sales to be invested in R&D in 2006–7
18,400 employees around the world |
Subscribe